Risk Disclosure: This website's content is not investment advice and offers no trading guidance or related services. Per regulations from the PBOC and other authorities, users must be aware of virtual currency risks. Contact us / support@techflowpost.com ICP License: 琼ICP备2022009338号
TechFlow news, December 2: According to market information, Sonnet Biotherapeutics, a Nasdaq-listed biotechnology company, has received shareholder approval for a proposed business combination with Hyperliquid Strategies Inc.
Previous report: Hyperliquid Strategies filed an S-1 form aiming to raise up to $1 billion, potentially used to purchase HYPE tokens.
Earlier news: Hyperliquid Strategies filed an S-1 form, aiming to raise up to $1 billion, potentially for purchasing HYPE tokens.
Navigating Web3 tides with focused insights
